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ABSTRACT 
 
RNA viruses show enormous capacity to evolve and adapt to new cellular and 
molecular contexts, a consequence of mutations arising from errors made by 
viral RNA-dependent RNA polymerase during replication. Sequence variation 
must occur, however, without compromising functions essential for the 
completion of the viral cycle. RNA viruses are safeguarded in this respect by 
their genome carrying conserved information that does not code only for 
proteins, but also for the formation of structurally conserved RNA domains that 
directly perform these critical functions. Functional RNA domains can interact 
with other regions of the viral genome and/or proteins to direct viral translation, 
replication and encapsidation. They are therefore potential targets for novel 
therapeutic strategies. This review summarizes our knowledge of the functional 
RNA domains of human RNA viruses, and examines the achievements made in 
the design of antiviral compounds that interfere with their folding, and therefore 
their function.  
 
Page 2 of 37Reviews in Medical Virology
For Review Only
3 
 
ABBREVIATIONS 
AFM, atomic force microscopy. 
CRE, cis-acting replicating element. 
DENV, Dengue virus.  
EMCV, encephalomyocardhitis virus.  
FMDV, foot and mouth disease virus.  
FRD, functional RNA domain. 
GORS, genome-scale ordered RNA structures.  
IF, initiation factor. 
hCoV, human coronavirus.  
HV, highly variable region. 
HVR, hypervariable region. 
IBV, infectious bronchitis virus. 
IGR, intergenic region. 
IRES, internal ribosome entry site.  
ITAF, initiator trans-acting factor.  
JEV, Japanese encephalitis virus. 
PABP, polyA binding protein.  
PCBP, poly-rC binding protein. 
PK, pseudoknot. 
PTB, polypyrimidine-tract binding protein. 
SELEX, systematic evolution of ligands by exponential enrichment. 
sp, specie. 
UTR, untranslatable region.  
YFV, yellow fever virus. 
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INTRODUCTION 
The appearance of viral mutants resistant to antiviral compounds is a major 
public health concern. The continuous generation of such mutants is a 
characteristic of RNA viruses, many of which, e.g., hepatitis C virus (HCV), 
human immunodeficiency virus (HIV), and dengue virus (DENV) (all with a 
single–stranded, positive RNA genome) cause serious disease. The genome of 
RNA viruses acts as both the template for replication and as mRNA. During 
replication, mutations are introduced into the genome via errors in the action of 
viral RNA-dependent RNA polymerase; this can generate mutants that may 
greatly contribute to viral proliferation – although it can also lead to the 
disappearance of the virus if such changes leave it non-viable or induce acute 
pathogenesis in the host, the so-called error catastrophe (for reviews, see [1,2]). 
Viruses must, therefore, strive to reach an equilibrium that allows for adaptive 
fitness without compromising their persistence. To accomplish this, RNA viruses 
have developed an information storage system that does not code for proteins, 
but for specific, complex and highly conserved, folded genomic regions that play 
direct, functional roles in the viral cycle. These viral regions present an adaptive 
behaviour that has evolved with the selective pressure to achieve high genetic 
robustness [3-5]. As a result, mutations in viral RNA genomes present minor 
incidence in the functional elements [4]. 
RNA molecules show two levels of compaction: their secondary and their 
tertiary structures. The secondary structure is the result of double and single-
stranded regions arrangements, e. g., helices closed by loops. The tertiary 
structure is determined by the relationships established between secondary 
structure elements. The combination of these two folding levels establishes the 
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final shape of the RNA, the so-called RNA structurome [6]. This conformational 
view of RNA molecules has prompted the search of structured RNA motifs as 
functional RNA domains (FRDs), not only in the viral genomes [7], but also in 
the transcriptome of all living organisms (for a review, see [6]).  
A main feature of FRDs included in viral genomes is their high genetic 
robustness, likely derived from their essentiality for the consecution of the 
infective cycle [3-5]. FRDs are cis-acting elements typically involved in RNA-
RNA and RNA-protein interactions, required for the correct execution and 
regulation of essential viral processes [8-10]. One of the FRDs that has 
attracted most attention is the internal ribosome entry site (IRES). IRES regions 
direct the recruitment of the cellular translation machinery in a cap-independent 
manner [11]. Similarly, viral replication and maturation are regulated by the 
direct binding of viral polymerases and related cofactors to FRDs in the 3’ end 
of the genomic RNA, as well as by direct RNA-RNA interactions between 
distant regions of the virus genome [12].  
The functional importance of structural elements in the viral cycle and their high 
conservation rate [8,9,13-15], suggests they might make good therapeutic 
targets, and the idea of developing novel antiviral tools (mostly RNA-based) to 
attack them has gained currency in recent years. This review briefly 
summarizes what is known about the FRDs of a number of viruses, paying 
special attention to those infecting humans, and recapitulates the state of the art 
in the development of therapeutic compounds that might interfere with FRD 
folding and, therefore, function. 
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VIRAL IRESs: RNA TAGS FOR EFFICIENT TRANSLATION 
Many viral genomes achieve the efficient translation initiation by the use of 
IRESs, which replace initiation factors (IFs) by the combined use of several 
FRDs. These regions present high sequence and structural diversity across 
different viral groups, which define the mechanisms by which they promote 
translation. IRESs are therefore divided into four groups [16] according to 
common IF requirements (Figure 1):  
- Packed IRESs. This group encompasses the IRES elements located in the 
intergenic region (IGR) of the genome of the Dicistroviridae family (whose 
members infect insects). The folding of these elements represents a highly 
conserved, compact structure that, via the so-called “all RNA-based” 
mechanism, mediates the recruitment of the ribosome with no need of 
additional protein factors [17]. The IRES structure can be split into three 
domains (Figure 1a), each defined by a pseudoknot motif (PKI-PKIII). This 
conformation is considered the “prefolded” isoform of the IRES. Domain PKIII 
mimics the folding of the initiator tRNA allowing it to occupy the P and E sites of 
the 40S ribosomal subunit. This promotes structural changes in the IRES that 
finally allow the binding of the 60S particle and the efficient initiation of 
translation from a non-AUG codon [17-22]. Thus, the conformation of PKIII 
replaces the need for an initiator tRNA [23].  
- Extended IRES with compact regions. The prototype of this group, the HCV 
IRES, folds as an extended region with tightly compact domains. It is mostly 
contained in the 5’UTR of the RNA genome but also spans a short stretch of the 
coding sequence (Figure 1b) [24,25]. It can be divided into two major domains 
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(II and III) [26] and a short stem-loop containing the start codon (domain IV) 
[27]. The extended folding of the IRES allows for the proper coaxial alignment of 
domains II and III on either side of a complex pseudoknot structure [28]. This 
allows easy access for the 40S ribosomal particle; subsequent IRES 
conformational changes directly position the appropriate start codon in the P 
site [29]. Then, binding of eIF3 at the IIIabc junction aids the incorporation of the 
ternary complex eIF2-tRNAi
Met and the joining of the 60S subunit (for a review, 
see [30]). Interestingly, the requirement for eIF2-tRNAi
Met can be minimized 
under certain stress conditions [31], providing a selective advantage for efficient 
HCV propagation even in unfavourable physiological environments. This 
suggests that an IRES may change its mode of function depending on 
environmental conditions. 
- Flexible IRESs.  These are mainly represented by picornavirus type II IRESs 
(FMDV and encephalomyocarditis virus [EMCV] among others; Figure 1c) [9]. 
Their overall 3D structure reflects a greater degree of flexibility than that shown 
by IGR or HCV-like IRESs before ribosomal recruitment [32-35]. Nonetheless, 
they retain compact self-folded stem-loops and a GNRA sequence motif 
included within a tetraloop that directs the structural organization of central 
domain 3 [32]. Flexible IRESs cannot directly recruit the 40S ribosomal subunit; 
rather, they first recruit eIF4G, eIF4A, eIF4B and eIF3 at domains 4-5 [36,37] to 
finally induce conformational rearrangements that promote the recruitment of 
the 43S complex. The presence of domains 2 and 3 is crucial since they bind 
additional initiator trans-acting factors (ITAFs), such as polypyrimidine-tract 
binding protein (PTB), polyA binding protein (PABP) and ITAF45 [38-41]. ITAFs 
are thought to provide chaperone activity but may also help overcome cell 
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restrictions under stress conditions. Hence, the flexible folding provides specific 
biophysical properties that define a characteristic mode of action. 
- Inducible IRES. In lentiviruses, the use of IRES elements is restricted to 
certain environmental conditions, the initiation of protein synthesis normally 
being accomplished by a cap-dependent mechanism. Two different IRES 
elements lie within the HIV genome: one in the 5’UTR, which only operates in 
the G2/M phase of the cell cycle [42,43], and one embedded within the coding 
sequence (Figure 1d) [42,44]. Enormous efforts have gone into fathoming the 
induction mechanism(s) of these elements, but without much success. It is well 
known that the 5’UTR of HIV-1 RNA can adopt two different conformations, but 
a direct translational regulation mediated by conformational exchanges in the 
genomic RNA has been ruled out [45]. Further, it seems likely that unknown 
ITAFs are differentially loaded by each conformer, providing a sophisticated and 
opportunistic viral strategy aimed at overcoming environmental difficulties. It is 
tempting to propose that the induction of the IRES within the coding sequence 
is further modulated by long distance RNA-RNA interactions with the 5’UTR, 
thus promoting alternative conformations that might regulate its functioning [46]. 
FUNCTIONAL DOMAINS LOCATED AT THE 3’UTR 
FRDs are needed in the 3’ end of viral genomes to promote the efficient binding 
of the polymerase and the regulation of the elongation step during RNA 
synthesis [7,12]. They are also important partners in the preservation of viral 
genomic stability and the control of processes mediated by the 5’ end [47]. The 
latter is mediated by the establishment of a dynamic cross-talk between both 
termini of the genomic RNA. The sequence and 3D structure of the 3’ cis-acting 
Page 8 of 37Reviews in Medical Virology
For Review Only
9 
 
domains are quite diverse, even among members of the same taxon (Figure 2), 
which must entail substantial differences in the mechanism of action if the same 
function is to be achieved. Such great complexity and variability precludes a 
detailed discussion of all of the 3’ RNA structures present in different RNA 
viruses; only those most extensively studied are therefore mentioned below. 
3’UTRs in the Picornaviridae  
- Enterovirus sp.: 
The genus Enterovirus includes human polioviruses, rhinoviruses and the 
human enteroviruses of groups B, C and D (which include different human 
coxsackieviruses). Their genomic RNA ends with the so-called oriR region, 
which is composed of a short, highly folded 3’UTR (75-100 nucleotides) capped 
by a polyA tail [48,49]. The oriR has been shown to play an important role in 
viral replication via its direct recruitment of viral RNA-dependent RNA 
polymerase and host cell factors such as PCBP (poly-rC binding protein), the La 
autoantigen and eEF1A [15]. Common architecture at the 3’UTR can be inferred 
for all the members of a same viral group (Figure 2a). Thus, rhinoviruses have a 
single stem-loop (named Y), polioviruses contain two stem-loops (X and Y), and 
coxsackieviruses have three consecutive stem-loops (X, Y and Z) [48]. The 
presence of two or more stem-loops defines a typical pseudoknot motif (PK) 
involving the apical loops of domains X and Y [50,51]. This pseudoknot may 
regulate dynamic spatial rearrangements in domains X and Y that fine-tune viral 
RNA synthesis [52,53]. Despite sequence diversity, enterovirus 3’UTR 
represents a good example of how RNA genome structure has diversified yet 
retains common essential functions. 
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- Aphtoviruses: 
FMDV is the prototype of the aphtovirus group. Its genome contains an 
essential oriR region at the 3’ end consisting of a well-defined 3’UTR of around 
90 nucleotides, plus a genetically encoded polyA tract (Figure 2b). The 3’UTR 
adopts a quasi-globular conformation defined by two stem-loops, SL1 and SL2. 
It was recently shown that, while the deletion of SL2 completely interferes with 
virus viability, mutants defective for SL1 only show reduced replication capacity 
[54]. The oriR region in aphtoviruses is also involved in translational control by 
the establishment of molecular bridges with the IRES element at the 5’ end of 
the viral genome [55].  
cis-Acting elements within the 3’ end of genomic Flaviviridae RNA 
- Hepacivirus sp.: 
The 3’UTR of the HCV genome is an evolutionarily conserved structural 
element of around 200 nucleotides with three different domains (Figure 2c): the 
highly variable region (HV), a polyU/UC tract of variable length and composition, 
and the 3’X tail consisting of three stem-loops (3’SLI-3’SLIII) [56,57]. Both the 
polyU/UC tract and the 3’X tail contain elements important in replication and 
infectivity in cell culture and a chimpanzee model [58-64]. The 3’UTR in 
hepaciviruses operates by the recruitment of viral proteins, such as RNA-
dependent RNA polymerase and helicase [65], as well as numerous host 
factors [66-70]. Moreover, the formation of high order structures involving RNA 
motifs in the 3’ end of the coding sequence provide additional regulation of 
3’UTR folding and activity [71,72]. Together, the above elements constitute the 
complete functional scaffold required to achieve precise RNA replication.   
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- Flavivirus sp.: 
This genus includes important human pathogens, such as DENV, yellow fever 
virus (YFV) and Japanese encephalitis virus (JEV). Their positive RNA genome 
contains a 3’UTR ranging from 350-700 nucleotides in length. Despite this 
heterogeneity in size, common secondary structure elements are found at the 
very 3’ end of the genomic RNA, defining the so-called domain III, which is 
indispensable for replication [73] (Figure 2d). Domain III is composed of a short 
hairpin followed by a long and stable stem-loop (3’SL). It has been shown that 
the formation of a pseudoknot motif involving the apical loop of the short hairpin 
and an internal loop of the 3’SL is critical for the recognition of viral and cellular 
proteins during the initiation of RNA synthesis [74].  
3’ terminal domains in coronaviruses 
The genome of the Coronaviridae family encodes for 5-7 overlapping, capped 
and polyadenylated subgenomic mRNAs [75]. The 3’UTR contains two highly 
conserved structural motifs: an essential bulge stem-loop (BSL) immediately 
followed by a hairpin (Figure 2e) [76,77]. Under certain conditions, this folding 
may be displaced towards the formation of a pseudoknot motif between the 
base of the first domain and the apical loop of the hairpin [78]. This leads to a 
conformational equilibrium that must be preserved for RNA replication to occur. 
At the 3’ position of the pseudoknot, a hypervariable region (HVR) is found. It is 
highly divergent both in terms of primary and secondary structure, with the 
exception of the 5’-GGAAGAGG-3’ motif. This octanucleotide is situated 70 to 
80 nts from the 3′ end of all coronaviruses genomes, thus being considered a 
characteristic signature of these pathogenic agents [75]. Such stringent 
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conservation implies a critical, yet unknown function, in the coronaviruses 
biology [79].  
A long list of viral and cellular proteins also bind the 3’UTR of different 
coronavirus and affect replication [75]. These include viral RNA polymerase, 
non-structural virus proteins, nuclear factors, and proteins involved in the 
translation process. Thus, once again, RNA-RNA and RNA-protein interactions 
provide a complex regulatory network that controls viral infection. 
CIS-ACTING RNA ELEMENTS WITHIN THE CODING SEQUENCE 
Recent work has shown a great variety of cis-acting RNA motifs embedded 
throughout the coding sequence [80-86]. These operate in a coordinated 
fashion with other functional regions and with viral and host proteins, providing 
complex control systems for replication. 
Some of the best characterized cis-acting replicating elements (CREs) are 
found in the picornavirus genome [87-89]. All of them contain one or more short 
hairpins responsible for efficient priming during RNA synthesis [90]. Two 
adenine residues placed in an apical loop of one of these hairpins function as 
template for the uridylylation of the essential viral protein VPg, involved in 
picornaviral replication [90]. This mechanism has been shown to contribute to 
the overcoming of the rate-limiting effects of low nucleotide concentrations [91], 
thus providing a robust system for the initiation of replication. 
A CRE element was identified within the 3’ end of the coding sequence of the 
HCV genome [81]. It is a highly conserved structure composed of three stem-
loops (5BSL3.1 to 5BSL3.3) (Figure 3a) [92], which was shown to be required 
for viral replication [64,93]. The establishment of long range RNA-RNA 
interactions between 5BSL3.2 and the 3’SLII within the 3’UTR [71,94-96], and 
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with the SL9110 hairpin motif in the coding sequence [72,95,96], is critical for 
the proper functioning of this region during viral RNA synthesis (Figure 3a) 
[71,72]. Importantly, the existence of an additional, direct, long-range RNA-RNA 
interaction involving the subdomain IIId of the IRES and the essential stem-loop 
5BSL3.2 of the CRE region has important consequences for the regulation of 
HCV IRES function (Figure 3a) [96-98]. 
5’-3’ COMMUNICATION IN VIRAL GENOMES 
End-to-end communication in viral genomes is directly responsible for 
promoting and regulating different steps of the infectious cycle. Via the 
establishment of long distance contacts, differentially evolved functional regions 
at both ends of viral genomes can act in a coordinated fashion to generate 
molecular switch control systems between different steps of the viral cycle. 
Such cross-talk seems to provide important benefits, such as an increase in the 
local concentration of essential proteins and cofactors, and additional protection 
against the action of exonucleases. Genome circularisation provides new proof 
of the great versatility shown by compact viral RNA genomes.  
The formation of the circular topology in picornaviruses is dependent on direct 
RNA contacts between the IRES and the 3’UTR (Figure 3b) [55]. Further, the 
RNA binding capacity of different factors, such as eIF4G to the IRES region, or 
PABP (polyA binding protein) to the 3’ polyA tail, ensures the stability of the 
closed-loop conformation.  
In hepacivirus genomes, circularisation was initially proposed to be mediated by 
protein factors alone [47], which would simultaneously bind to both ends of the 
viral genome. More recently, a long range contact between the IRES and the 
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CRE element was described to induce significant conformational changes in 
precise domains of the IRES (Figure 3a) [97,99], resulting in the regulation of 
IRES function [98]. Undoubtedly, these results do not exclude the participation 
of viral and cellular proteins in the stabilization of circular topology, nor the 
performance of important functional roles [100-103].  
In other viruses, such as Flavivirus sp., the formation of the circular topology 
does not require the presence of proteins but the use of canonical and 
complementary sequences (CS, cyclization sequence; UAR, upstream AUG 
region; and DAR, downstream AUG region) at either end of the viral genome 
[104-106] (Figure 3c). These motifs achieve the association of the genomic 
termini by direct base-pairing. The closed-loop topology is essential for viral 
propagation and could be very advantageous for the regulation of viral 
translation and RNA synthesis, as well for the control of the switch between 
different steps of the viral cycle.  
VIRAL RNA STRUCTURES AS NOVEL TARGETS FOR THERAPEUTIC 
AGENTS 
Complex viral evolutionary dynamics are a great obstacle in the development of 
efficient therapeutic tools. The constant appearance of sequence mutants 
resistant to current treatments has prompted the search for alternative targets. 
Structurally conserved regions involved in the progression of the viral cycle are 
excellent candidates. The combining of different compounds targeting multiple 
viral regions and processes might contribute greatly to reducing the appearance 
of resistant variants. The following section summarizes the main advances 
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recently made in the development of molecules directed against different 
functional domains of viral RNA genomes. 
Nucleic acids-based drugs 
Nucleic acids, particularly RNA, are excellent candidates for the development of 
antiviral agents targeting functional regions of viral genomes. The success of 
these strategies relies on sequence complementarity and/or structural 
recognition between the inhibitor and the target. Therefore, highly conserved 
genomic domains are the most promising regions for targeting new nucleic 
acids-based antiviral compounds. Importantly, a number of aspects need to be 
taken into account in pursuing this goal [107], such as the cellular uptake of the 
inhibitor, target and inhibitor colocalization, the active inhibitor concentration 
inside the cell, the intracellular inhibitor stability and the access and binding to 
the target region. In recent years, great progress has been made in the field of 
nucleic acid treatment and some of the above problems have been now 
successfully solved. This has led to the design of new generations of antiviral 
RNA and DNA drugs that are currently being extensively developed [108].  
- Antisense oligonucleotides:  
Antisense oligonucleotides are short nucleic acid molecules whose sequence 
is complementary to an existing motif in a target RNA. The molecular 
mechanisms of action of antisense oligonucleotides are diverse (Figure 4a) 
[109]. They act by hiding essential sites in the viral genomic RNA, such as 
those required for protein synthesis, replication and packaging; or if DNA-
based, by inducing target degradation mediated by RNase H [108].  
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Antisense oligonucleotides can be administered either directly, by 
subcutaneous injection, or as pharmacological compositions. In this context, 
great advances in the combinatorial chemistry have allowed for the 
development of oligonucleotides with chemical substitutions at precise positions 
[108]. These modifications confer important features, such as significant half-life 
increase in serum and higher thermal stability of the duplex [110]. This strategy 
was followed by McHutchinson et al. for the design of an anti-HCV compound 
[111], but with low success in Phase I clinical trials. 
A different administration strategy is based on the intracellular production of 
unmodified antisense oligonucleotides. It requires gene therapy protocols to 
deliver the construct inside the cell. Its main advantage is that chimeric 
constructs encompassing different antisense sequences (or even different 
nucleic-acid based inhibitors) can be produced, thus targeting multiple sites 
simultaneously. The use of this strategy may greatly contribute to diminish the 
appearance of viral resistant variants. This method has been successfully used 
for the inhibition of the HIV-1 replication [112-114]. 
- Small interfering RNAs (siRNAs): 
The cellular RNAi pathway can be triggered by synthetic double-stranded small 
interfering RNA molecules (siRNAs). These compounds are usually 21 
nucleotides long, with a two-nucleotide 3’ overhang. The siRNAs are loaded into 
the RISC (RNA-induced silencing complex), where the sense, guide strand is 
selected to target the complementary sequence within the genomic viral RNA 
for further degradation (Figure 4a) [115]. 
To date, numerous studies have been conducted using siRNAs as antiviral 
drugs [115]. Importantly, previous advances made for the therapeutic use of 
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antisense oligonucleotides have served as starting point for the development of 
this new strategy. Thus, the incorporation of stabilizing chemical modifications 
in the passenger (antisense) strand may greatly increase the potency of the 
siRNA without toxicity [116]. 
The application of gene therapy strategies to promote long-term decrease of 
viral loads has been also studied for the siRNA technology. One of the main 
drawbacks of this alternative is the appearance of escape mutants [117]. To 
overcome this problem, several strategies have been developed based in the 
generation of constructs combining multiple siRNAs targeting different regions 
of the viral genomes [118]. 
The great potential of siRNA-based therapeutics has prompted the development 
of novel internalization strategies that should allow for a better sustained 
antiviral response. Important contributions have been made in the field for the 
HCV infection. For example, the use of nanosomes (lipidic nanoparticles) 
achieves the encapsulation of multiple siRNAs with a 100% of delivery yield in a 
liver tumor-xenotransplant mouse model of HCV [119]. Alternatively, 
multilayered polyelectrolyte films (MPFs) have been also shown to be an 
efficient way of nucleic acids intracellular delivery, providing dose-dependent, 
specific, and long-term inhibition of HCV replication in hepatocyte-derived cells 
[120].  
- Aptamers: 
Aptamers are nucleic acids that bind to a specific ligand with high affinity. They 
are isolated by SELEX (systematic evolution of ligands by exponential 
enrichment), an in vitro selection strategy [121,122]. This process consists of 
iterative series of the synthesis, binding, positive selection and amplification of a 
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randomised oligonucleotide pool to yield a population enriched in those 
molecules that can bind to a desired target molecule (Figure 4b). This strategy 
has identified RNA and DNA molecules of potential therapeutic use in a great 
variety of diseases, including many viral infections [123]. In addition, aptamers 
offer useful information about the 3D architecture of the target molecule. They 
are therefore a valuable alternative to complementary oligonucleotides 
(antisense and siRNAs). An aptamer’s mode of action is dependent on its 
folding and mediated by direct loop-loop interactions (Figure 4b), which block 
the function of the RNA target domain, either by interfering with the recruitment 
of essential factors, or by affecting the folding of the surrounding area and thus 
impeding RNA-RNA interactions, or both. This may contribute to diminish the 
chance of appearance of resistant viral mutants. 
Among the preferred viral targets, the most extensively investigated has been 
the 5’UTR, including that of the genomic RNA of HIV [124-129] and HCV [130-
133]. Other functional RNA regions have been used as targets for aptamers, 
such as the 3’UTR [130] and the CRE region of HCV [134]. These inhibitors 
have returned promising results both in cell culture and in vitro, and have been 
used to produce antiviral compounds efficient in the nanomolar range [135,136]. 
Further, this research has served as a starting point for the development of 
novel strategies combining two or more inhibitor RNA molecules [137-142].  
The emergence of SELEX methodologies has provided novel therapeutic and 
diagnostic agents with improved pharmacokinetic and pharmacodynamic 
properties and low immunogenicity. These compounds are already being 
investigated by several companies for possible clinical use (reviewed in [143]). 
The conjugation of the 5’ end of the aptamer sequence with stabilizing agents 
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such as polyethylene glycol (PEG) has been shown very effective in 
pharmacological formulations [144]. The additional incorporation of ligands for 
specific cell surface receptors helps in the efficient and precise delivery of 
agents to target cell types or tissues. Given the great progress being made in 
this field, aptamers may be in widespread use as antiviral agents in the future.  
Antibiotics against RNA functional domains 
The use of antibiotics for targeting RNA structural elements was firstly 
described for the aminoglycoside paramomycin. This compound recognizes the 
aminoacyl A site of the bacterial ribosome by its interaction with an enlarged 
deep grove defined by two bulging and one unpaired adenine residues 
[145,146]. This 3D conformation was shown to be strongly similar to that 
acquired by the HIV-1 DIS (dimerization initiation site) kissing–loop complex 
[147]. Further modelling and crystal structure resolution provided strong basis 
for the development of modified, high affinity antivirals derived from 
aminoglycosides [148]. Even more, these studies have recently provided a 
more accurate view of the folding of the HIV DIS region [149]. These results will 
greatly prompt the design of small, improved ligands able to interfere with the 
folding of the essential DIS domain.   
Branched peptides targeting the TAR element of HIV 
Branched peptides are a common therapeutic tool used in the development of 
synthetic peptide vaccines and drug delivery vehicles [150]. Their usefulness as 
efficient ligands of RNA molecules is associated with the latter carrying so-
called multivalent targets, i.e., functional RNA domains with multiple interacting 
sites. Additionally, amino acids may carry a radical of specific molecular 
architecture that increases the target selectivity. These molecules have been 
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isolated from random peptide libraries to generate efficient, non-toxic and cell-
permeable antiviral compounds that target the HIV TAR element [151]. 
Benzimidazole derivatives 
The benzimidazole nucleus is the main constituent of many therapeutic drugs, 
all of them based on the combination of heterocyclic compounds to yield 
isosters of naturally occurring nucleotides. The chemical composition of these 
isosters makes benzimidazole derivatives excellent candidates for interaction 
with natural biopolymers. One of these derivatives, ISIS-11, has attracted much 
attention in recent years as a potential anti-HCV molecule. This compound 
specifically interacts with the basal portion of the IRES domain II, the so-called 
domain IIa [152,153]. During the recruitment of the 40S ribosomal particle, 
domain II adopts an L-shape that directs the apical hairpin loop IIb toward the 
40S subunit E site, thus inducing a conformational shift that promotes the 
positioning of the start codon close to the active site. In the presence of ISIS-11, 
domain IIa acquires the shape of an open helix that alters the proper folding of 
domain II, thus impeding the correct positioning of the viral RNA in the catalytic 
binding cleft. These findings confirm the important principle of interfering with 
RNA folding to achieve an inhibitory effect. 
CONCLUDING REMARKS 
The compactness of RNA viral genomes provides important advantages in 
terms of propagation efficiency. Such compactness, however, requires the 
intervention of a supracoding system (i.e., information in the genome beyond 
that of the nucleotide sequence) to direct the folding required; without such a 
supracoding system, no such compactness would exist and essential functions 
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of the genome in transcription, replication and encapsidation associated with 
this folding would be lost. Structurally conserved functional RNA elements 
interact with protein factors and other RNA domains to direct and regulate these 
functions as well as switching between different steps of the viral cycle. 
Interfering with the functioning of these structural domains offers a potential 
means of treating viral infections. The great advances made in the field of 
chemical synthesis and nucleic acid production has prompted novel initiatives 
involving small molecules that can alter the 3D conformation of viral genomic 
RNA domains. This might be used to complement classical antiviral therapies, 
such as the use of neutralizing antibodies or interferon treatment. The 
combination of clinical strategies is currently under extensive investigation with 
the aim of improving therapeutic responses and long-term outcomes while 
minimizing toxicity and secondary effects.   
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FIGURE LEGENDS  
Figure 1. Diagram showing the secondary structure of different types of viral 
IRESs. a) Dicistroviridae IGR (intergenic region) IRES. b) HCV, with the 
minimum IRES region boxed. c) FMDV IRES. d) HIV-1 IRES elements. 
Functional domains are shadowed or indicated as noted. Start translation 
codons are marked by arrows. PK, pseudoknots.  
Figure 2. Diagram showing the structural diversity of the 3’UTRs of different 
viruses. a) Several examples of 3’UTRs of enterovirus, b) aphtoviruses, c) HCV, 
d) Flavivirus sp., and e) the Coronaviridae family. Proposed pseudoknot 
structures (PK) are indicated with a line. Structural motifs defining functional 
RNA elements are noted. Stop codons are marked by an arrow. BSL, bulge 
stem-loop; HV, highly variable region; HVR, hypervariable region; N, any 
nucleotide; R, purine. 
Figure 3. Circularisation mechanisms in different viral genomic RNA molecules. 
Detailed diagrams of the secondary structure proposed for the 5’ and 3’ ends, 
as well as for the described CREs, are shown. a) HCV. The region required for 
IRES activity is noted. The 3’ end of the viral genomic RNA is organized into 
two structural elements: the CRE region and the 3’UTR. b) FMDV RNA genome 
with the VPg viral protein bound to its 5’ end. The IRES region is indicated. 
Binding sites for eIF4G and polyA binding protein (PABP) are shadowed. The 
circular form is stabilized by protein-protein (eIF4G and PABP, among others) 
and RNA-RNA interactions. c) Flavivirus genome capped at its 5’ end (indicated 
by m7G) to ensure viral protein synthesis. The locations of the complementary 
sequences CS, UAR and DAR are marked by grey solid lines. The black solid 
Page 32 of 37Reviews in Medical Virology
For Review Only
33 
 
lines indicate long-distance interactions (direct RNA-RNA and protein-protein 
contacts). Arrows denote the position of the start and stop translation codons. 
Pseudoknots (PK) are noted as described in Figure 1.  
Figure 4. Nucleic acid-based antiviral compounds. a) Mechanism of action for 
antisense oligonucleotides and siRNAs. RNase H mediates the cleavage of the 
heteroduplex antisense deoxyoligonucleotide:target RNA. For non-DNA 
oligomers, inhibition is achieved by directing the oligonucleotides against 
functional regions of the RNA, such as those involved in the recruitment of the 
translational or replicative machinery. siRNAs bind to the macromolecular 
complex RISC, which selects the guide strand that recognizes the target 
sequence in the RNA of interest. This promotes the RNA degradation by 
specific endonucleases. b) Diagram of a SELEX process to identify RNA 
aptamers targeting a specific RNA domain. Suppression of transcription and 
reverse transcription allows for the isolation of active DNA aptamers.  
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